Myrcludex B eligible for EMA PRIME scheme

26 May 2017
2019_biotech_test_vial_discovery_big

The European Medicines Agency has granted "PRIME eligibility" for Myrcludex B, a first in class entry inhibitor for hepatitis Delta (D) virus, under development by Germany biotech firm MYT GmbH and its partner Hepatera, a Russian drugmaker.

"It is very encouraging that the European regulator recognizes the importance of the unmet medical problem in hepatitis delta and is willing to support the development of Myrcludex B," said Heiner Wedemeyer, Professor at Hannover Medical School and chairman of MYR's clinical advisory board. "The affected patients are in urgent need of new medications and we are looking forward to the upcoming results of the Phase IIb program with this innovative drug."

"The combined efforts of academic research, public funding and small biotech development and venture activities allowed the clinical development of a completely new drug with a novel mode of action on both Hepatitis B and D virus. The enhanced dialog with EMA will now strongly facilitate further joint effort to bring Myrcludex B to the HDV/HBV co-infected patients in need as fast as possible," commented Stephan Urban, DZIF-Professor for Translational Virology at the University of Heidelberg, inventor of the technology and collaboration partner of MYR and Hepatera.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology